TXMD · TherapeuticsMD, Inc.
$2.06
-0.01 (-0.48%)
At close · Jul 28
View the 10-Q filed May 12, 2026
Going-concern doubt
— flagged May 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements.”View the 10-Q filed May 12, 2026
Customer concentration
— top 3 customers 100% of revenue
3 customers — 100% of revenue (the three months ended March 31, 2026)
“For the three months ended March 31, 2026, 100% of license revenue related to Mayne Pharma, Theramex and Knight.”
Market Cap
$23.84M
Shares
11.57M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Marlan D. Walker | CEO | $759,174 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Michael Donegan | CFO | $1,286,663 |
| Marlan D. Walker | CEO | $1,019,817 |
| Joseph Ziegler | Principal Financial and Accounting Officer | $82,900 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Brian Bernick | CEO | $1,624,016 |
| Marlan D. Walker | CEO | $1,573,380 |
| Michael Donegan | CFO | $914,240 |
| James D’Arecca | CFO | $207,890 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| James D’Arecca | CFO | $1,721,654 |
| Marlan D. Walker | CEO | $1,597,193 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Edward Borkowski | Executive Vice President, Operations | $4,477,154 |
| Robert Finizio | CEO | $2,746,536 |
| John C.K. Milligan | President and Secretary | $2,275,390 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| John C.K. Milligan | President and Secretary | $1,440,639 |
| Robert Finizio | CEO | $1,222,220 |
| Mitchell Krassan | Chief Strategy and Performance Officer | $1,044,994 |
| Daniel A. Cartwright | CFO | $1,014,578 |
| Michael Donegan | Interim CFO | $572,084 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Robert Finizio | CEO | $2,724,577 |
| John C.K. Milligan | President and Secretary | $1,701,434 |
| Daniel A. Cartwright | CFO | $1,245,477 |
| Mitchell Krassan | Chief Strategy and Performance Officer | $1,129,352 |
| Michael Donegan | Interim CFO | $703,480 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Robert Finizio | CEO | $2,983,955 |
| John C.K. Milligan | President and Secretary | $1,840,029 |
| Daniel A. Cartwright | CFO | $1,352,785 |
| Mitchell Krassan | Chief Strategy and Performance Officer | $1,221,410 |
| Michael Donegan | Interim CFO | $531,491 |